223 related articles for article (PubMed ID: 30096444)
21. [Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery].
Chen T; Hou SX; Sun YY; Zheng Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov; 37(6):934-7. PubMed ID: 17236598
[TBL] [Abstract][Full Text] [Related]
22. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
Li J; Xu H; Ke X; Tian J
J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
[TBL] [Abstract][Full Text] [Related]
23. Improved anti-melanoma effect of a transdermal mitoxantrone ethosome gel.
Yu X; Du L; Li Y; Fu G; Jin Y
Biomed Pharmacother; 2015 Jul; 73():6-11. PubMed ID: 26211575
[TBL] [Abstract][Full Text] [Related]
24. [Vemurafenib (Zelboraf) in the therapy of melanoma].
Liszkay G
Magy Onkol; 2013 Jun; 57(2):110-3. PubMed ID: 23795356
[TBL] [Abstract][Full Text] [Related]
25. A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor
Yang Y; Tai X; Shi K; Ruan S; Qiu Y; Zhang Z; Xiang B; He Q
Theranostics; 2016; 6(12):2141-2160. PubMed ID: 27698946
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
27. Factorial design based curcumin ethosomal nanocarriers for the skin cancer delivery:
Peram MR; Jalalpure S; Kumbar V; Patil S; Joshi S; Bhat K; Diwan P
J Liposome Res; 2019 Sep; 29(3):291-311. PubMed ID: 30526186
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
29. Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma.
Saraswat A; Vartak R; Hegazy R; Fu Y; Rao TJR; Billack B; Patel K
Biomed Pharmacother; 2023 Dec; 168():115754. PubMed ID: 37871557
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
[TBL] [Abstract][Full Text] [Related]
31. Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma.
Kato J; Hida T; Kamiya T; Sato S; Takahashi H; Torigoe T; Uhara H
JAMA Dermatol; 2018 May; 154(5):621-622. PubMed ID: 29590278
[No Abstract] [Full Text] [Related]
32. Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.
Meier-Davis SR; Dines K; Arjmand FM; Hamlin R; Huang B; Wen J; Christianson C; Shudo J; Nagata T
Cutan Ocul Toxicol; 2012 Dec; 31(4):312-7. PubMed ID: 22515841
[TBL] [Abstract][Full Text] [Related]
33. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
34. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
[TBL] [Abstract][Full Text] [Related]
35. Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine-docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo.
Zhang J; Yang C; Pan S; Shi M; Li J; Hu H; Qiao M; Chen D; Zhao X
Drug Deliv; 2018 Nov; 25(1):723-737. PubMed ID: 29513049
[TBL] [Abstract][Full Text] [Related]
36. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
[TBL] [Abstract][Full Text] [Related]
37. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
38. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
40. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
